pCF221 Citations (2)

Originally described in: CRISPR-Cas9 Circular Permutants as Programmable Scaffolds for Genome Modification.
Oakes BL, Fellmann C, Rishi H, Taylor KL, Ren SM, Nadler DC, Yokoo R, Arkin AP, Doudna JA, Savage DF Cell. 2019 Jan 10;176(1-2):254-267.e16. doi: 10.1016/j.cell.2018.11.052. PubMed Journal

Articles Citing pCF221

Articles
Targeted delivery of CRISPR-Cas9 and transgenes enables complex immune cell engineering. Hamilton JR, Tsuchida CA, Nguyen DN, Shy BR, McGarrigle ER, Sandoval Espinoza CR, Carr D, Blaeschke F, Marson A, Doudna JA. Cell Rep. 2021 Jun 1;35(9):109207. doi: 10.1016/j.celrep.2021.109207. PubMed Associated Plasmids pJRH029 pCAT001 pJRH051 pCAT003 pCAT005 More ...
Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells. Tsuchida CA, Brandes N, Bueno R, Trinidad M, Mazumder T, Yu B, Hwang B, Chang C, Liu J, Sun Y, Hopkins CR, Parker KR, Qi Y, Satpathy AT, Stadtmauer EA, Cate JHD, Eyquem J, Fraietta JA, June CH, Chang HY, Ye CJ, Doudna JA. bioRxiv. 2023 Mar 22:2023.03.22.533709. doi: 10.1101/2023.03.22.533709. Preprint. PubMed

If you have published an article using this material, please email us at [email protected] to have your article added to this page.